| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vismodegib |
| Brand | Erivedge® |
| Indication | For the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 02/05/2013 |
| Rapid review completed | 20/05/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 16/09/2013 |
| NCPE assessment completed | 21/01/2014 |
| NCPE assessment outcome | Reimbursement not recommended |
The HSE has approved reimbursement following confidential price negotiations October 2017.
